Concepts (678)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 48 | 2022 | 8161 | 3.630 |
Why?
|
| Blood Pressure | 38 | 2021 | 8528 | 2.990 |
Why?
|
| Ventricular Dysfunction, Left | 27 | 2020 | 2042 | 2.780 |
Why?
|
| Cardiovascular Diseases | 55 | 2022 | 14075 | 2.770 |
Why?
|
| Ventricular Remodeling | 23 | 2021 | 1280 | 2.150 |
Why?
|
| Echocardiography | 37 | 2021 | 5139 | 2.130 |
Why?
|
| Ventricular Function, Left | 29 | 2021 | 3411 | 2.100 |
Why?
|
| Heart Failure | 52 | 2021 | 10040 | 1.870 |
Why?
|
| Hypertrophy, Left Ventricular | 13 | 2022 | 867 | 1.770 |
Why?
|
| Sex Characteristics | 7 | 2022 | 2510 | 1.760 |
Why?
|
| Metabolome | 11 | 2017 | 859 | 1.730 |
Why?
|
| Atherosclerosis | 25 | 2021 | 3228 | 1.470 |
Why?
|
| Coronary Vessels | 6 | 2022 | 2964 | 1.230 |
Why?
|
| Heart Ventricles | 13 | 2021 | 3851 | 1.150 |
Why?
|
| Brachial Artery | 6 | 2017 | 374 | 1.140 |
Why?
|
| Heart Diseases | 9 | 2021 | 2759 | 1.090 |
Why?
|
| Carotid Arteries | 7 | 2021 | 977 | 1.070 |
Why?
|
| Aging | 8 | 2022 | 8358 | 1.050 |
Why?
|
| Echocardiography, Doppler | 11 | 2018 | 972 | 1.030 |
Why?
|
| Carbon Monoxide | 4 | 2020 | 543 | 0.990 |
Why?
|
| Risk Factors | 98 | 2021 | 69553 | 0.980 |
Why?
|
| Myocardium | 13 | 2022 | 4969 | 0.980 |
Why?
|
| Myocardial Contraction | 6 | 2015 | 1659 | 0.960 |
Why?
|
| Middle Aged | 159 | 2022 | 213752 | 0.940 |
Why?
|
| Male | 198 | 2022 | 349524 | 0.940 |
Why?
|
| Prehypertension | 3 | 2017 | 61 | 0.910 |
Why?
|
| Longitudinal Studies | 33 | 2021 | 13536 | 0.910 |
Why?
|
| Sex | 1 | 2022 | 60 | 0.910 |
Why?
|
| Stroke Volume | 27 | 2021 | 4522 | 0.900 |
Why?
|
| Female | 196 | 2022 | 375205 | 0.890 |
Why?
|
| Hypercholesterolemia | 3 | 2018 | 1167 | 0.890 |
Why?
|
| Hemodynamics | 9 | 2021 | 4211 | 0.860 |
Why?
|
| Aged | 127 | 2022 | 161488 | 0.860 |
Why?
|
| Health Status Disparities | 3 | 2018 | 1711 | 0.840 |
Why?
|
| Metabolomics | 8 | 2019 | 1357 | 0.820 |
Why?
|
| Humans | 251 | 2022 | 708843 | 0.810 |
Why?
|
| Seroepidemiologic Studies | 2 | 2021 | 359 | 0.800 |
Why?
|
| Heart | 9 | 2021 | 4315 | 0.790 |
Why?
|
| Natriuretic Peptide, Brain | 15 | 2020 | 1574 | 0.780 |
Why?
|
| Obesity | 16 | 2020 | 12031 | 0.780 |
Why?
|
| Diastole | 12 | 2020 | 836 | 0.770 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2021 | 117 | 0.770 |
Why?
|
| Adult Children | 1 | 2020 | 103 | 0.770 |
Why?
|
| Pulmonary Edema | 3 | 2020 | 418 | 0.760 |
Why?
|
| Coronary Circulation | 5 | 2020 | 1652 | 0.720 |
Why?
|
| Microcirculation | 2 | 2020 | 1301 | 0.710 |
Why?
|
| Electrocardiography | 10 | 2021 | 6386 | 0.700 |
Why?
|
| Sex Factors | 21 | 2022 | 10566 | 0.700 |
Why?
|
| Adipokines | 2 | 2018 | 298 | 0.690 |
Why?
|
| Coronary Disease | 7 | 2019 | 6127 | 0.660 |
Why?
|
| African Americans | 11 | 2021 | 5118 | 0.640 |
Why?
|
| Pacemaker, Artificial | 3 | 2011 | 762 | 0.630 |
Why?
|
| Aged, 80 and over | 50 | 2021 | 58184 | 0.630 |
Why?
|
| Vascular Diseases | 3 | 2022 | 1154 | 0.620 |
Why?
|
| Antibodies, Viral | 5 | 2021 | 2930 | 0.620 |
Why?
|
| Atrial Function, Left | 4 | 2019 | 165 | 0.610 |
Why?
|
| Prognosis | 41 | 2021 | 28919 | 0.610 |
Why?
|
| Antihypertensive Agents | 7 | 2021 | 2046 | 0.600 |
Why?
|
| Natriuretic Peptides | 3 | 2011 | 140 | 0.590 |
Why?
|
| Coronary Artery Disease | 12 | 2021 | 6213 | 0.580 |
Why?
|
| Isocitrates | 1 | 2015 | 25 | 0.580 |
Why?
|
| Longevity | 3 | 2016 | 1019 | 0.580 |
Why?
|
| Taurocholic Acid | 1 | 2015 | 43 | 0.570 |
Why?
|
| Diabetes Mellitus | 14 | 2022 | 5348 | 0.570 |
Why?
|
| Systole | 10 | 2017 | 993 | 0.570 |
Why?
|
| Incidence | 26 | 2021 | 20320 | 0.550 |
Why?
|
| Risk Assessment | 34 | 2021 | 23284 | 0.550 |
Why?
|
| Massachusetts | 18 | 2019 | 8712 | 0.540 |
Why?
|
| Multivariate Analysis | 19 | 2021 | 12447 | 0.540 |
Why?
|
| Age of Onset | 7 | 2021 | 3330 | 0.530 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2015 | 168 | 0.530 |
Why?
|
| Adult | 74 | 2022 | 211041 | 0.530 |
Why?
|
| Diabetes Complications | 3 | 2020 | 1394 | 0.510 |
Why?
|
| Age Factors | 18 | 2021 | 18712 | 0.510 |
Why?
|
| Cardiomyopathies | 4 | 2022 | 1819 | 0.500 |
Why?
|
| Health Personnel | 4 | 2021 | 2983 | 0.500 |
Why?
|
| Smoking | 8 | 2022 | 8612 | 0.500 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2013 | 78 | 0.500 |
Why?
|
| Hospitalization | 6 | 2022 | 9644 | 0.500 |
Why?
|
| Cardiomyopathy, Hypertrophic | 4 | 2022 | 1195 | 0.480 |
Why?
|
| Cardiovascular System | 3 | 2016 | 767 | 0.480 |
Why?
|
| Peptide Fragments | 10 | 2020 | 5141 | 0.470 |
Why?
|
| Cohort Studies | 33 | 2022 | 39292 | 0.470 |
Why?
|
| American Heart Association | 4 | 2020 | 973 | 0.470 |
Why?
|
| Los Angeles | 3 | 2021 | 210 | 0.450 |
Why?
|
| Leisure Activities | 2 | 2016 | 294 | 0.450 |
Why?
|
| Myocardial Infarction | 11 | 2021 | 11323 | 0.450 |
Why?
|
| United States | 45 | 2022 | 67165 | 0.450 |
Why?
|
| Family Health | 1 | 2017 | 1276 | 0.440 |
Why?
|
| Predictive Value of Tests | 24 | 2021 | 15252 | 0.430 |
Why?
|
| Exhalation | 2 | 2020 | 175 | 0.430 |
Why?
|
| Adiposity | 5 | 2020 | 1734 | 0.420 |
Why?
|
| Pericytes | 1 | 2013 | 259 | 0.410 |
Why?
|
| Proportional Hazards Models | 16 | 2021 | 12292 | 0.390 |
Why?
|
| Growth Differentiation Factor 15 | 5 | 2014 | 161 | 0.390 |
Why?
|
| Myocardial Ischemia | 5 | 2020 | 2114 | 0.380 |
Why?
|
| Amino Acids, Branched-Chain | 4 | 2020 | 233 | 0.380 |
Why?
|
| Ultrasonography | 10 | 2020 | 5918 | 0.370 |
Why?
|
| Heart Block | 1 | 2011 | 410 | 0.370 |
Why?
|
| Pyrroles | 2 | 2013 | 1182 | 0.360 |
Why?
|
| Heart Atria | 5 | 2018 | 1286 | 0.360 |
Why?
|
| Outpatients | 2 | 2018 | 1349 | 0.360 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2009 | 49 | 0.360 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 366 | 0.360 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1224 | 0.350 |
Why?
|
| Microvessels | 1 | 2013 | 565 | 0.350 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2021 | 3418 | 0.350 |
Why?
|
| Critical Care | 2 | 2021 | 2473 | 0.350 |
Why?
|
| Bundle-Branch Block | 1 | 2010 | 276 | 0.340 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2016 | 815 | 0.340 |
Why?
|
| Prevalence | 18 | 2019 | 14712 | 0.340 |
Why?
|
| Research Design | 3 | 2022 | 5833 | 0.340 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 335 | 0.340 |
Why?
|
| Atrioventricular Block | 1 | 2009 | 110 | 0.340 |
Why?
|
| Prospective Studies | 39 | 2021 | 50597 | 0.340 |
Why?
|
| Eicosanoids | 2 | 2020 | 260 | 0.340 |
Why?
|
| Abdominal Fat | 1 | 2009 | 224 | 0.330 |
Why?
|
| Receptors, Cell Surface | 7 | 2014 | 2913 | 0.330 |
Why?
|
| Linear Models | 10 | 2021 | 5986 | 0.330 |
Why?
|
| Troponin T | 3 | 2019 | 753 | 0.330 |
Why?
|
| Pulsatile Flow | 5 | 2016 | 334 | 0.330 |
Why?
|
| Electronic Health Records | 2 | 2021 | 4173 | 0.320 |
Why?
|
| Indoles | 2 | 2013 | 1857 | 0.320 |
Why?
|
| Blood Glucose | 8 | 2021 | 6255 | 0.320 |
Why?
|
| Aorta, Abdominal | 1 | 2010 | 705 | 0.320 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2021 | 8968 | 0.310 |
Why?
|
| Calcinosis | 2 | 2018 | 1435 | 0.310 |
Why?
|
| Insulin Resistance | 9 | 2021 | 3866 | 0.310 |
Why?
|
| Albuminuria | 4 | 2020 | 675 | 0.310 |
Why?
|
| Cross-Sectional Studies | 21 | 2021 | 23020 | 0.310 |
Why?
|
| Vitamin D Deficiency | 3 | 2014 | 1356 | 0.310 |
Why?
|
| Peripheral Arterial Disease | 2 | 2022 | 1206 | 0.310 |
Why?
|
| Enoxaparin | 1 | 2009 | 361 | 0.310 |
Why?
|
| Lipids | 5 | 2020 | 3246 | 0.310 |
Why?
|
| Health Surveys | 1 | 2017 | 3994 | 0.310 |
Why?
|
| Bone Marrow Cells | 2 | 2011 | 2596 | 0.300 |
Why?
|
| Manometry | 4 | 2019 | 419 | 0.300 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2022 | 15485 | 0.300 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2010 | 847 | 0.300 |
Why?
|
| Cholesterol | 4 | 2021 | 2866 | 0.290 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2021 | 555 | 0.290 |
Why?
|
| Time Factors | 23 | 2021 | 41038 | 0.290 |
Why?
|
| Stroke | 8 | 2020 | 9256 | 0.290 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 664 | 0.290 |
Why?
|
| Coronary Thrombosis | 1 | 2009 | 487 | 0.280 |
Why?
|
| Troponin I | 6 | 2020 | 632 | 0.280 |
Why?
|
| Prediabetic State | 3 | 2015 | 468 | 0.280 |
Why?
|
| Workflow | 2 | 2022 | 803 | 0.280 |
Why?
|
| Blood Pressure Determination | 2 | 2020 | 607 | 0.270 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3153 | 0.270 |
Why?
|
| Body Mass Index | 14 | 2020 | 12366 | 0.270 |
Why?
|
| Asymptomatic Diseases | 3 | 2018 | 577 | 0.270 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3275 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2020 | 10857 | 0.270 |
Why?
|
| Case-Control Studies | 10 | 2021 | 21194 | 0.270 |
Why?
|
| Long QT Syndrome | 2 | 2020 | 415 | 0.270 |
Why?
|
| Phenotype | 10 | 2021 | 16306 | 0.270 |
Why?
|
| Chromatography, Liquid | 3 | 2019 | 959 | 0.270 |
Why?
|
| Blood | 2 | 2022 | 624 | 0.270 |
Why?
|
| Ventricular Function | 2 | 2021 | 427 | 0.260 |
Why?
|
| Genetic Loci | 4 | 2019 | 2587 | 0.260 |
Why?
|
| Follow-Up Studies | 23 | 2020 | 39038 | 0.250 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 1422 | 0.250 |
Why?
|
| Ankle Brachial Index | 4 | 2022 | 166 | 0.250 |
Why?
|
| Heart Rate | 6 | 2020 | 4094 | 0.250 |
Why?
|
| Lung | 4 | 2020 | 9706 | 0.250 |
Why?
|
| Diagnostic Imaging | 2 | 2017 | 3495 | 0.240 |
Why?
|
| Young Adult | 15 | 2021 | 55940 | 0.240 |
Why?
|
| Atrial Fibrillation | 7 | 2018 | 4454 | 0.240 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2021 | 2301 | 0.230 |
Why?
|
| Adipose Tissue | 2 | 2018 | 3234 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2067 | 0.230 |
Why?
|
| Genome-Wide Association Study | 10 | 2022 | 11738 | 0.230 |
Why?
|
| Oxylipins | 2 | 2020 | 50 | 0.230 |
Why?
|
| Cardiomegaly | 2 | 2018 | 653 | 0.230 |
Why?
|
| Motor Activity | 1 | 2012 | 2749 | 0.230 |
Why?
|
| Odds Ratio | 7 | 2022 | 9754 | 0.220 |
Why?
|
| Disease Progression | 6 | 2018 | 13298 | 0.220 |
Why?
|
| Barbering | 1 | 2021 | 7 | 0.220 |
Why?
|
| Retinal Vein | 1 | 2021 | 48 | 0.220 |
Why?
|
| Community Pharmacy Services | 1 | 2021 | 42 | 0.210 |
Why?
|
| Heparin | 1 | 2009 | 1625 | 0.210 |
Why?
|
| Awareness | 1 | 2005 | 597 | 0.210 |
Why?
|
| Aortic Diseases | 2 | 2020 | 725 | 0.210 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2021 | 91 | 0.210 |
Why?
|
| Mass Spectrometry | 3 | 2019 | 2244 | 0.210 |
Why?
|
| Triglycerides | 6 | 2021 | 2564 | 0.210 |
Why?
|
| Cause of Death | 4 | 2017 | 3497 | 0.200 |
Why?
|
| Algorithms | 4 | 2021 | 13647 | 0.200 |
Why?
|
| Telemedicine | 3 | 2021 | 2583 | 0.200 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2022 | 240 | 0.200 |
Why?
|
| Stem Cells | 2 | 2011 | 3593 | 0.190 |
Why?
|
| Retrospective Studies | 15 | 2022 | 71483 | 0.190 |
Why?
|
| Blood Flow Velocity | 4 | 2020 | 1468 | 0.190 |
Why?
|
| Glucose Tolerance Test | 3 | 2018 | 1156 | 0.190 |
Why?
|
| Lactobacillus | 1 | 2020 | 181 | 0.180 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2019 | 1115 | 0.180 |
Why?
|
| Severity of Illness Index | 8 | 2021 | 16008 | 0.180 |
Why?
|
| Azithromycin | 1 | 2020 | 180 | 0.180 |
Why?
|
| Reproducibility of Results | 9 | 2022 | 19423 | 0.180 |
Why?
|
| Patient Compliance | 2 | 2021 | 2758 | 0.180 |
Why?
|
| Stress, Mechanical | 2 | 2015 | 1714 | 0.180 |
Why?
|
| Vitamin D | 2 | 2011 | 3138 | 0.180 |
Why?
|
| Neoplasms | 5 | 2021 | 20172 | 0.180 |
Why?
|
| Vasodilation | 2 | 2015 | 968 | 0.180 |
Why?
|
| Pandemics | 5 | 2021 | 7089 | 0.180 |
Why?
|
| C-Reactive Protein | 7 | 2020 | 3696 | 0.180 |
Why?
|
| Sphingolipids | 1 | 2020 | 160 | 0.180 |
Why?
|
| Atrial Function, Right | 1 | 2018 | 36 | 0.180 |
Why?
|
| Parents | 3 | 2017 | 3154 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2021 | 17218 | 0.170 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2018 | 116 | 0.170 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 629 | 0.170 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2017 | 389 | 0.170 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2021 | 247 | 0.170 |
Why?
|
| Ceramides | 1 | 2019 | 193 | 0.170 |
Why?
|
| BCG Vaccine | 1 | 2021 | 354 | 0.170 |
Why?
|
| Risk Reduction Behavior | 3 | 2020 | 1110 | 0.170 |
Why?
|
| Preventive Health Services | 2 | 2021 | 583 | 0.170 |
Why?
|
| Dyslipidemias | 3 | 2016 | 843 | 0.170 |
Why?
|
| Biological Factors | 1 | 2019 | 164 | 0.170 |
Why?
|
| Tibial Arteries | 1 | 2017 | 59 | 0.160 |
Why?
|
| Cardiac Volume | 1 | 2018 | 214 | 0.160 |
Why?
|
| Inhalation Exposure | 1 | 2020 | 441 | 0.160 |
Why?
|
| Immunoglobulin G | 4 | 2021 | 4422 | 0.160 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 579 | 0.160 |
Why?
|
| Neprilysin | 1 | 2020 | 425 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 582 | 0.160 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 437 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2021 | 851 | 0.160 |
Why?
|
| Aorta | 3 | 2014 | 2120 | 0.160 |
Why?
|
| Amyloid | 1 | 2021 | 710 | 0.160 |
Why?
|
| Sodium, Dietary | 1 | 2020 | 409 | 0.160 |
Why?
|